AXSANA is a behemoth international prospective observational study analyzing outcomes after different axillary procedures for clinically node-positive breast cancer following neoadjuvant systemic therapy, and so far it is clear complete nodal responses are driven by tumor biology (86% for HR- HER2+, 71% for HR+HER2+, 69% for triple-negative, and 31% for HR+ HER2-) and not extent of disease (54% for 1-3 clinically-involved nodes versus…54% for 4+). | Banys-Paluchowski, ASCO 2026
